Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.
Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA
Mol Cell Biol. 2020 Sep 28;40(20). doi: 10.1128/MCB.00341-20.
Lysine demethylase 6A (KDM6A), also known as UTX, belongs to the KDM6 family of histone H3 lysine 27 (H3K27) demethylases, which also includes UTY and KDM6B (JMJD3). The KDM6A protein contains six tetratricopeptide repeat (TPR) domains and an enzymatic Jumonji C (JmjC) domain that catalyzes the removal of di- and trimethylation on H3K27. KDM6A physically associates with histone H3 lysine 4 monomethyltransferases MLL3 (KMT2C) and MLL4 (KMT2D). Since its identification as an H3K27 demethylase in 2007, studies have reported KDM6A's critical roles in cell differentiation, development, and cancer. KDM6A is important for differentiation of embryonic stem cells and development of various tissues. Mutations of KDM6A cause Kabuki syndrome. KDM6A is frequently mutated in cancers and functions as a tumor suppressor. KDM6A is redundant with UTY and functions largely independently of its demethylase activity. It regulates gene expression, likely through the associated transcription factors and MLL3/4 on enhancers. However, KDM6A enzymatic activity is required in certain cellular contexts. Functional redundancy between H3K27 demethylase activities of KDM6A and KDM6B has yet to be determined. Further understanding of KDM6A functions and working mechanisms will provide more insights into enhancer regulation and may help generate novel therapeutic approaches to treat KDM6A-related diseases.
赖氨酸去甲基化酶 6A(KDM6A),也称为 UTX,属于组蛋白 H3 赖氨酸 27(H3K27)去甲基酶家族,该家族还包括 UTY 和 KDM6B(JMJD3)。KDM6A 蛋白包含六个四肽重复(TPR)结构域和一个酶 Jumonji C(JmjC)结构域,该结构域催化 H3K27 的二甲基化和三甲基化的去除。KDM6A 与组蛋白 H3 赖氨酸 4 单甲基转移酶 MLL3(KMT2C)和 MLL4(KMT2D)物理结合。自 2007 年被鉴定为 H3K27 去甲基酶以来,研究报告称 KDM6A 在细胞分化、发育和癌症中具有关键作用。KDM6A 对于胚胎干细胞的分化和各种组织的发育很重要。KDM6A 的突变会导致歌舞伎综合征。KDM6A 在癌症中经常发生突变,作为肿瘤抑制因子发挥作用。KDM6A 与 UTY 冗余,并在很大程度上独立于其去甲基酶活性发挥作用。它通过相关的转录因子和增强子上的 MLL3/4 调节基因表达。然而,在某些细胞环境中需要 KDM6A 的酶活性。KDM6A 和 KDM6B 的 H3K27 去甲基酶活性之间的功能冗余尚未确定。进一步了解 KDM6A 的功能和工作机制将为增强子调控提供更多的见解,并可能有助于开发治疗 KDM6A 相关疾病的新治疗方法。